FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248580043> ?p ?o ?g. }

• W4248580043 endingPage "4548" @default.
• W4248580043 startingPage "4548" @default.
• W4248580043 abstract "Abstract Background: Despite major advances in the treatment of multiple myeloma (MM) only a minority of patients achieve long-term disease control. Immunotherapy combined with autologous hematopoietic stem cell transplantation (auto-HCT) may reduce relapse rates. Immunoglobulin idiotype (Id) conjugated with a carrier protein, Keyhole limpet hemocyanin (KLH), is a tumor-specific antigen in MM. Vaccine-primed, anti-CD3/anti-CD28 costimulated adoptive T-cell transfer can augment humoral and cellular immune responses to vaccination despite cytotoxic therapy. We hypothesized that Id-KLH vaccine + the vaccine-primed costimulated T cells will result in a robust Id-specific humoral and cellular response, compared to a control vaccine (KLH only). Methods: In this randomized, phase II trial, the primary objective was to determine if Id-KLH primed, costimulated T cells will induce a more robust Id-specific immunity than KLH-primed T cells. Eligible patients had IgG monoclonal protein. Patients were randomized 1:1 to receive either Id-KLH vaccine or KLH-only vaccine, followed by auto-HCT, and then vaccine- primed costimulated T cells followed by two booster doses of the vaccine to which they were randomized. This study was supported by The MD Anderson Cancer Center SPORE in Multiple Myeloma. Results: A total of 36 patients were enrolled between 1/2013 and 5/2015. Sixteen (44%) were randomized to Id-KLH and 20 (55%) to KLH-only. The Table below summarizes the patient characteristics. There was no significant difference between the two groups in terms of age, risk status or induction therapy. No treatment-related mortality, infusion reactions or dose-limiting toxicity was seen in either arm. Five (31%) and 3 (15%) patients achieved complete remission (CR) by day+180 in the Id-KLH and KLH arms, respectively (p=0.42). Initial analysis of a subgroup of patients revealed a significantly higher mRNA expression of immune activation genes IL-2, CCR6 and CD40 by NanoString nCounter in the Id-KLH group compared with the KLH only group (Figure). Eleven (68%) and 17 (85%) went on to receive maintenance therapy with lenalidomide or lenalidomide + ixazomib in the Id-KLH and KLH arms, respectively (p=0.42). After a median follow up of 26 months, 2-year PFS was 81% and 83% in Id-KLH and KLH arms, respectively (p=0.35). Conclusion: Id-KLH vaccine and vaccine-primed costimulated T cells can be safely administered in the setting of auto-HCT.There was a more robust immune response and a trend towards higher CR rate in the Id-KLH group. Disclosures Stadtmauer: Teva: Consultancy; Amgen: Consultancy; Novartis: Consultancy; Takada: Consultancy; Janssen: Consultancy; Celgene: Consultancy. Garfall:Medimmune: Consultancy; Bioinvent: Research Funding; Novartis: Consultancy, Research Funding. Cohen:Janssen: Consultancy; Bristol-Meyers Squibb: Consultancy, Research Funding. June:Johnson & Johnson: Research Funding; Immune Design: Consultancy, Equity Ownership; Novartis: Honoraria, Patents & Royalties: Immunology, Research Funding; University of Pennsylvania: Patents & Royalties; Celldex: Consultancy, Equity Ownership; Tmunity: Equity Ownership, Other: Founder, stockholder ; Pfizer: Honoraria." @default.
• W4248580043 created "2022-05-12" @default.
• W4248580043 creator A5008558372 @default.
• W4248580043 creator A5008785159 @default.
• W4248580043 creator A5013826719 @default.
• W4248580043 creator A5015342719 @default.
• W4248580043 creator A5025168585 @default.
• W4248580043 creator A5029801761 @default.
• W4248580043 creator A5035811221 @default.
• W4248580043 creator A5038235561 @default.
• W4248580043 creator A5048913229 @default.
• W4248580043 creator A5053904944 @default.
• W4248580043 creator A5055885795 @default.
• W4248580043 creator A5055929208 @default.
• W4248580043 creator A5057254430 @default.
• W4248580043 creator A5060313982 @default.
• W4248580043 creator A5063622933 @default.
• W4248580043 creator A5066752969 @default.
• W4248580043 creator A5068834306 @default.
• W4248580043 creator A5072396796 @default.
• W4248580043 creator A5074671045 @default.
• W4248580043 creator A5074743570 @default.
• W4248580043 creator A5079740127 @default.
• W4248580043 creator A5081679403 @default.
• W4248580043 creator A5086011253 @default.
• W4248580043 creator A5088930582 @default.
• W4248580043 creator A5090432539 @default.
• W4248580043 date "2016-12-02" @default.
• W4248580043 modified "2023-09-26" @default.
• W4248580043 title "Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation" @default.
• W4248580043 doi "https://doi.org/10.1182/blood.v128.22.4548.4548" @default.
• W4248580043 hasPublicationYear "2016" @default.
• W4248580043 type Work @default.
• W4248580043 citedByCount "7" @default.
• W4248580043 countsByYear W42485800432017 @default.
• W4248580043 countsByYear W42485800432018 @default.
• W4248580043 countsByYear W42485800432019 @default.
• W4248580043 countsByYear W42485800432020 @default.
• W4248580043 countsByYear W42485800432021 @default.
• W4248580043 crossrefType "journal-article" @default.
• W4248580043 hasAuthorship W4248580043A5008558372 @default.
• W4248580043 hasAuthorship W4248580043A5008785159 @default.
• W4248580043 hasAuthorship W4248580043A5013826719 @default.
• W4248580043 hasAuthorship W4248580043A5015342719 @default.
• W4248580043 hasAuthorship W4248580043A5025168585 @default.
• W4248580043 hasAuthorship W4248580043A5029801761 @default.
• W4248580043 hasAuthorship W4248580043A5035811221 @default.
• W4248580043 hasAuthorship W4248580043A5038235561 @default.
• W4248580043 hasAuthorship W4248580043A5048913229 @default.
• W4248580043 hasAuthorship W4248580043A5053904944 @default.
• W4248580043 hasAuthorship W4248580043A5055885795 @default.
• W4248580043 hasAuthorship W4248580043A5055929208 @default.
• W4248580043 hasAuthorship W4248580043A5057254430 @default.
• W4248580043 hasAuthorship W4248580043A5060313982 @default.
• W4248580043 hasAuthorship W4248580043A5063622933 @default.
• W4248580043 hasAuthorship W4248580043A5066752969 @default.
• W4248580043 hasAuthorship W4248580043A5068834306 @default.
• W4248580043 hasAuthorship W4248580043A5072396796 @default.
• W4248580043 hasAuthorship W4248580043A5074671045 @default.
• W4248580043 hasAuthorship W4248580043A5074743570 @default.
• W4248580043 hasAuthorship W4248580043A5079740127 @default.
• W4248580043 hasAuthorship W4248580043A5081679403 @default.
• W4248580043 hasAuthorship W4248580043A5086011253 @default.
• W4248580043 hasAuthorship W4248580043A5088930582 @default.
• W4248580043 hasAuthorship W4248580043A5090432539 @default.
• W4248580043 hasConcept C147483822 @default.
• W4248580043 hasConcept C159654299 @default.
• W4248580043 hasConcept C203014093 @default.
• W4248580043 hasConcept C22070199 @default.
• W4248580043 hasConcept C2776090121 @default.
• W4248580043 hasConcept C2776727803 @default.
• W4248580043 hasConcept C2777701055 @default.
• W4248580043 hasConcept C542903549 @default.
• W4248580043 hasConcept C71924100 @default.
• W4248580043 hasConcept C74505204 @default.
• W4248580043 hasConcept C8891405 @default.
• W4248580043 hasConcept C90375314 @default.
• W4248580043 hasConceptScore W4248580043C147483822 @default.
• W4248580043 hasConceptScore W4248580043C159654299 @default.
• W4248580043 hasConceptScore W4248580043C203014093 @default.
• W4248580043 hasConceptScore W4248580043C22070199 @default.
• W4248580043 hasConceptScore W4248580043C2776090121 @default.
• W4248580043 hasConceptScore W4248580043C2776727803 @default.
• W4248580043 hasConceptScore W4248580043C2777701055 @default.
• W4248580043 hasConceptScore W4248580043C542903549 @default.
• W4248580043 hasConceptScore W4248580043C71924100 @default.
• W4248580043 hasConceptScore W4248580043C74505204 @default.
• W4248580043 hasConceptScore W4248580043C8891405 @default.
• W4248580043 hasConceptScore W4248580043C90375314 @default.
• W4248580043 hasIssue "22" @default.
• W4248580043 hasLocation W42485800431 @default.
• W4248580043 hasOpenAccess W4248580043 @default.
• W4248580043 hasPrimaryLocation W42485800431 @default.
• W4248580043 hasRelatedWork W1484759019 @default.
• W4248580043 hasRelatedWork W1972479046 @default.
• W4248580043 hasRelatedWork W2042230752 @default.
• W4248580043 hasRelatedWork W2150135081 @default.
• W4248580043 hasRelatedWork W2220102944 @default.

• next